Advertisement
U.S. Markets closed

Verve Therapeutics, Inc. (VERV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
5.55-0.10 (-1.77%)
At close: 04:00PM EDT
5.55 0.00 (0.00%)
After hours: 04:20PM EDT
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
20,648
11,758
1,941
0
0
-
Operating Expense
242,613
234,882
167,628
87,067
40,627
-
Operating Income
-221,965
-223,124
-165,687
-87,067
-40,627
-
Net Non Operating Interest Income Expense
27,747
23,166
6,867
142
162
-
Other Income Expense
1,838
165
1,486
-33,389
-5,239
-
Pretax Income
-192,380
-199,793
-157,334
-120,314
-45,704
-
Tax Provision
271
275
53
0
0
-
Net Income Common Stockholders
-192,651
-200,068
-157,387
-120,314
-45,704
-
Diluted NI Available to Com Stockholders
-192,651
-200,068
-157,387
-120,314
-45,704
-
Basic EPS
-3.08
-3.12
-2.91
-4.48
-1.57
-
Diluted EPS
-3.08
-3.12
-2.91
-4.48
-1.57
-
Basic Average Shares
62,129
64,175
54,024
26,872
29,174
-
Diluted Average Shares
63,737
64,175
54,024
26,872
29,174
-
Total Operating Income as Reported
-221,965
-223,124
-165,687
-87,067
-40,627
-
Total Expenses
242,613
234,882
167,628
87,067
40,627
-
Net Income from Continuing & Discontinued Operation
-192,651
-200,068
-157,387
-120,314
-45,704
-
Normalized Income
-192,651
-200,068
-157,387
-120,314
-45,704
-
Interest Income
-
-
-
-
162
278
Net Interest Income
27,747
23,166
6,867
142
162
-
EBIT
-221,965
-223,124
-165,687
-87,067
-40,627
-
EBITDA
-215,675
-217,669
-162,883
-85,532
-39,299
-
Reconciled Depreciation
6,290
5,455
2,804
1,535
1,328
-
Net Income from Continuing Operation Net Minority Interest
-192,651
-200,068
-157,387
-120,314
-45,704
-
Normalized EBITDA
-215,675
-217,669
-162,883
-85,532
-39,299
-
Tax Rate for Calcs
0
0
0
0
0
-
Tax Effect of Unusual Items
0
0
0
0
0
-